Cardiovascular adverse effects of immune checkpoint inhibitors

Agnieszka Socha; Agata Prokopiuk; Agata Kornacka; Emilia Babula; Katarzyna Kołodziejczyk; Tomasz Dzierżanowski

doi:10.5114/pm.2024.138609

eISSN: 2081-2833
ISSN: 2081-0016

Medycyna Paliatywna/Palliative Medicine

Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

1/2024
vol. 16

Send email

Copy url:

abstract:

Guidelines/recommendations

Cardiovascular adverse effects of immune checkpoint inhibitors

Agnieszka Socha

¹

,

Agata Prokopiuk

¹

,

Agata Kornacka

¹

,

Emilia Babula

¹

,

Katarzyna Kołodziejczyk

¹

,

Tomasz Dzierżanowski

^{1, 2}

Klinika Medycyny Paliatywnej, Warszawski Uniwersytet Medyczny, Warszawa, Polska
Caritas Diecezji Warszawsko-Praskiej

Medycyna Paliatywna 2024; 16(1): 6–14

DOI: https://doi.org/10.5114/pm.2024.138609

Online publish date: 2024/04/22

View full text Get citation

PlumX metrics:

Immune checkpoint inhibitors (ICI) are approved as first-line therapy for multiple cancers and significantly improve patients’ prognoses. However, they can also cause immune-related adverse events, among which cardiac adverse events are rare but highly lethal. Therefore, it is important to understand the spectrum of cardiac manifestations, because early detection and treatment are crucial to reduce the mortality. While myocarditis is the most common cardiac adverse event, other manifestations include takotsubo and dilated cardiomyopathy, pericarditis, pericardial effusion, cardiac tamponade, arrhythmia, giant cell arteritis, and atherosclerosis. Incidence ranges from 3.1% with monotherapy to 5.8% with combination therapy. Mortality reaches up to 50% in myocarditis and 26% in arrhythmia. Risk factors include older age, male gender, black race, and cardiovascular disease, but combination therapy is the most established predictor of cardiac adverse events. This article aims to present the spectrum of ICI cardiac adverse events and epidemiological data regarding those therapy complications.

keywords:

Cardiovascular adverse effects of immune checkpoint inhibitors

Agnieszka Socha 1 , Agata Prokopiuk 1 , Agata Kornacka 1 , Emilia Babula 1 , Katarzyna Kołodziejczyk 1 , Tomasz Dzierżanowski 1, 2

cardiotoxicity, immune checkpoint inhibitors, ICI, cardiac adverse events, CAE

Agnieszka Socha

¹

,

Agata Prokopiuk

¹

,

Agata Kornacka

¹

,

Emilia Babula

¹

,

Katarzyna Kołodziejczyk

¹

,

Tomasz Dzierżanowski

^{1, 2}